RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors

Lenny van Mechelen; Willem Luytjes; Cornelis A M de Haan; Oliver Wicht

doi:10.1016/j.antiviral.2016.05.003

RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors

Lenny van Mechelen, Willem Luytjes, Cornelis A M de Haan, Oliver Wicht

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Palivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However, virus neutralization assays generally omit Fc region-mediated effects. We investigated the neutralization activity of RSV-specific monoclonal antibodies on cells with Fc receptors. Subneutralizing concentrations of antibodies resulted in antibody-dependent enhancement of RSV infection in monocytic cells. Contrary to antibodies targeting other epitopes, the neutralization by palivizumab was augmented in cells with Fc receptors. This unrecognized characteristic of palivizumab may be relevant for its performance in vivo.

Original language	English
Pages (from-to)	1-5
Number of pages	5
Journal	Antiviral Research
Volume	132
DOIs	https://doi.org/10.1016/j.antiviral.2016.05.003
Publication status	Published - Aug 2016

Access to Document

10.1016/j.antiviral.2016.05.003

RSVFinal published version, 1.11 MBLicence: CC BY

Cite this

@article{d2fec8304fe04cf9be486635b968a952,

title = "RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors",

abstract = "Palivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However, virus neutralization assays generally omit Fc region-mediated effects. We investigated the neutralization activity of RSV-specific monoclonal antibodies on cells with Fc receptors. Subneutralizing concentrations of antibodies resulted in antibody-dependent enhancement of RSV infection in monocytic cells. Contrary to antibodies targeting other epitopes, the neutralization by palivizumab was augmented in cells with Fc receptors. This unrecognized characteristic of palivizumab may be relevant for its performance in vivo.",

author = "{van Mechelen}, Lenny and Willem Luytjes and {de Haan}, {Cornelis A M} and Oliver Wicht",

year = "2016",

month = aug,

doi = "10.1016/j.antiviral.2016.05.003",

language = "English",

volume = "132",

pages = "1--5",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier",

}

TY - JOUR

T1 - RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors

AU - van Mechelen, Lenny

AU - Luytjes, Willem

AU - de Haan, Cornelis A M

AU - Wicht, Oliver

PY - 2016/8

Y1 - 2016/8

N2 - Palivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However, virus neutralization assays generally omit Fc region-mediated effects. We investigated the neutralization activity of RSV-specific monoclonal antibodies on cells with Fc receptors. Subneutralizing concentrations of antibodies resulted in antibody-dependent enhancement of RSV infection in monocytic cells. Contrary to antibodies targeting other epitopes, the neutralization by palivizumab was augmented in cells with Fc receptors. This unrecognized characteristic of palivizumab may be relevant for its performance in vivo.

AB - Palivizumab efficiently blocks respiratory syncytial virus (RSV) infection in vitro. However, virus neutralization assays generally omit Fc region-mediated effects. We investigated the neutralization activity of RSV-specific monoclonal antibodies on cells with Fc receptors. Subneutralizing concentrations of antibodies resulted in antibody-dependent enhancement of RSV infection in monocytic cells. Contrary to antibodies targeting other epitopes, the neutralization by palivizumab was augmented in cells with Fc receptors. This unrecognized characteristic of palivizumab may be relevant for its performance in vivo.

U2 - 10.1016/j.antiviral.2016.05.003

DO - 10.1016/j.antiviral.2016.05.003

M3 - Article

C2 - 27185625

SN - 0166-3542

VL - 132

SP - 1

EP - 5

JO - Antiviral Research

JF - Antiviral Research

ER -

RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors

Abstract

Access to Document

Fingerprint

Cite this